HiFiBiO Cambridge
HiFiBiO Therapeutics is a private clinical-stage biotech using its proprietary DIS® single-cell and AI/ML platform to discover and develop immunotherapies for cancer and inflammatory diseases, monetising assets primarily through out-licensing and milestone-based partnerships with pharmaceutical companies.
- Company typePrivate
- Founded2017
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What HiFiBiO Cambridge does
HiFiBiO Therapeutics is a private, clinical-stage biotherapeutics company developing immunotherapies for cancer and immunology & inflammation (I&I) diseases. The company is built around its proprietary Drug Intelligence Science (DIS®) platform, which combines single-cell screening technology — embodied in the CelliGo™ microfluidic system capable of screening millions of species-agnostic B cells within hours — with AI/ML-driven bioinformatics (AbSolution™) for antibody binding prediction, affinity maturation, target discovery, and predictive biomarker identification. HiFiBiO has internally discovered 8 clinical candidates, cleared 6 INDs, and completed 4 Phase I dose-escalation trials; its active clinical pipeline includes the TNFR2 agonist emunkitug (HFB200301), the BTLA antagonist HFB200603, the OX40 agonist nuvustotug (HFB301001), and the BTLA agonist HFB200604 in I&I.
The company operates laboratory and operational facilities across three continents — Cambridge (US headquarters), Paris (France, original single-cell platform site), Shanghai, Hangzhou, and Hong Kong (China) — and pursues an open-innovation business model centred on out-licensing and co-development. Revenue is generated via upfront payments, development and commercial milestones, and royalties from partners rather than direct product sales; the landmark FibroGen agreement (June 2021) delivered $25M upfront plus up to $1.1B in potential milestones across three programs, followed by a $35M option exercise payment for the CCR8 program in December 2021. Novartis has entered clinical-supply agreements for combination studies with tislelizumab, and HiFiBiO participates in the REMISSION consortium under the France 2030 Initiative. No products are commercially approved, and the company is funded by a $75M Series D (2021) alongside prior venture capital from IDG Capital, Mirae Asset Capital, HongShan, and Nest.Bio Ventures.
HiFiBiO Cambridge firmographics
Firmographics- Name
- HiFiBiO Cambridge
- Legal name
- HiFiBiO Therapeutics, Inc.
- Website
- https://hifibio.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- HiFiBiO Therapeutics is a private clinical-stage biotech using its proprietary DIS® single-cell and AI/ML platform to discover and develop immunotherapies for cancer and inflammatory diseases, monetising assets primarily through out-licensing and milestone-based partnerships with pharmaceutical companies.
- Ownership category
- akta.pro rank
HiFiBiO Cambridge industry classification
Industry- Product category
- Clinical-stage biotherapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
Keywords
Where HiFiBiO Cambridge is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
HiFiBiO Cambridge business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Partnership and Licensing Revenue: HiFiBiO generates revenue through upfront payments, milestone payments (clinical, regulatory, commercial), and royalties on net sales from partnered programs. Examples include the FibroGen partnership generating $25M upfront plus up to $1.1B in milestones across three programs, and a $35M option exercise payment for the CCR8 program.
- Internal Pipeline Development and Commercialization: Development and potential commercialization of proprietary immunotherapies targeting cancer and autoimmune diseases through the company's internal pipeline of clinical-stage programs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
HiFiBiO Cambridge product offering
Product offeringCore offering
HiFiBiO Therapeutics is a clinical-stage biotech that develops transformative immunotherapies for cancer and autoimmune diseases using its proprietary Drug Intelligence Science (DIS®) platform, which combines single-cell technology with AI/ML analytics. The company advances an internal pipeline of monoclonal antibody candidates (e.g., Emunkitug, Nuvustotug, HFB200603, HFB200604) and monetizes select assets through out-licensing and co-development partnerships with pharmaceutical companies.
Product overview
HiFiBiO Therapeutics is a clinical-stage biotech with a platform-plus-pipeline architecture. The core is the Drug Intelligence Science (DIS®) platform, which combines proprietary single-cell technology with AI/ML analytics to drive immunotherapy discovery and development. DIS® is comprised of the CelliGo™ microfluidic antibody discovery system and AbSolution™ bioinformatics software. The company advances a sustainable pipeline of immunomodulatory antibodies targeting both immuno-oncology (IO) and immunology & inflammation (I&I) diseases. The IO pipeline includes three Phase I clinical programs: Emunkitug (TNFR2 agonist), Nuvustotug (OX40 agonist), and HFB200603 (BTLA antagonist). The I&I pipeline includes HFB200604 (BTLA agonist, IND cleared) and preclinical programs (HFB3024, HFB100204, HFB2025). The company maintains strategic partnerships including FibroGen (Galectin-9, CXCR5, CCR8 programs) and Novartis (clinical supply for tislelizumab combinations).
Differentiator
Problem solved
Functional benefit
Products and services
- DIS® Platform (Drug Intelligence Science) Proprietary translational platform combining single-cell technology with AI/ML analytics used by HiFiBiO and its partners to identify novel targets, select antibody drug candidates, and define predictive biomarkers for patient stratification across immuno-oncology and immunology & inflammation (I&I) programs.
- CelliGo™ Microfluidic-based screening platform that enables rapid identification of antibody candidates by screening millions of species-agnostic B cells within hours, supporting antibody discovery from patient samples.
- AbSolution™ Bioinformatics and machine-learning software for analyzing single B cell sequencing data, guiding antibody binding prediction and affinity maturation within the DIS® platform workflow.
- Emunkitug (HFB200301)
Quantifiable outcome
- 8 clinical candidates discovered and advanced, including first-in-class and best-in-class programs
- +4 more outcomes
Companies that use HiFiBiO Cambridge
Customer profileSegments2 records
Ideal customer profiles2 records
HiFiBiO Cambridge technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
HiFiBiO Cambridge partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, flagship and minor.
- UMass Chan Medical SchoolcoreGrant-funded collaboration with UMass Chan Medical School to research Long COVID and ME/CFS using HiFiBiO's DIS® platform for single-cell profiling of patient samples. Investigators include Dr. Liisa Selin and Dr. Anna Gil. The research focuses on immune repertoire profiling and identifying targets of B and T cell responses.
- Institut Gustave RoussyflagshipHiFiBiO joined the REMISSION consortium (Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology) under France 2030 Initiative, led by Institut Gustave Roussy. The company facilitates access to its three clinical-stage IO programs and applies DIS® for treatment optimization. This is a flagship collaboration involving academic and industry leaders.
- France 2030 InitiativeflagshipThe France 2030 Initiative funds the REMISSION consortium for personalized immunotherapies based on immune profiling rather than tumor histology. HiFiBiO is a key industry contributor to this national initiative.
- NovartiscoreClinical supply agreement for evaluation of HFB200301 (TNFR2 agonist) in combination with tislelizumab in DIS®-selected advanced solid tumors. Novartis supplies tislelizumab; HiFiBiO maintains global R&D and commercial rights for HFB200301.
- NovartiscoreClinical trial supply agreement with Novartis to evaluate HFB200603 (BTLA antagonist) in combination with tislelizumab (Novartis' anti-PD-1) in DIS®-selected advanced solid tumors. Novartis supplies tislelizumab while HiFiBiO maintains control of the HFB200603 program including global R&D and commercial rights.
- FibroGencoreFibroGen exercised its exclusive license option for HiFiBiO's anti-CCR8 monoclonal antibody program (HFB1011/HFB101110). HiFiBiO received a $35M option exercise payment plus potential milestones and royalties. FibroGen has sole right to develop all products worldwide.
- FibroGencoreFibroGen exclusively licensed HiFiBiO's Galectin-9 program and obtained exclusive options for CXCR5 and CCR8 programs. HiFiBiO received $25M upfront plus up to $1.1B in future milestones across all three programs plus royalties. The partnership represents significant validation of the DIS® approach.
- World-renowned Industry and Academic ResearchersminorOpen-innovation partnerships with industry leaders and academic researchers for collaborative research on disease biology, translational medicine, and immune profiling.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
HiFiBiO Cambridge competitors and assessment
Company assessmentDirect peers
- Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated immunotherapies for cancer with a platform approach (PREDATOR), directly competing with HiFiBiO in next-generation IO biologics and seeking pharma partnerships to advance assets.
- Compass Therapeutics: Clinical-stage antibody biotech with multiple IO programs (CTX-009, CTX-471, CTX-112) targeting similar immuno-oncology mechanisms, also pursuing a discovery platform-plus-pipeline model with partnership optionality.
- Adagene: Clinical-stage antibody biotech with a POWERbody and SAFEbody platform for conditionally activated antibodies in oncology, pursuing IO clinical assets with a similar platform-plus-pipeline approach as HiFiBiO.
- Compugen: Computational biology-driven biotech that uses AI/bioinformatics to discover novel IO targets and has its own clinical-stage antibody pipeline, sharing HiFiBiO's AI/ML-enabled biologic discovery orientation.
- Atreca: Clinical-stage antibody biotech using immune-repertoire sequencing and single-cell analysis to discover therapeutic antibodies directly from patient samples, a methodology that closely parallels HiFiBiO's DIS(R) single-cell approach.
- NextCure: Clinical-stage biotech developing immunomedicines for cancer and autoimmune disease with both an IO and I&I pipeline, structurally similar to HiFiBiO in its therapeutic-area breadth and antibody-centric approach.
- Cue Biopharma: Clinical-stage biotech developing rationally designed Immuno-STAT biologics for selective T cell modulation in cancer and autoimmune disease, working in overlapping IO/I&I indications with HiFiBiO.
- Inhibrx Biosciences: Clinical-stage antibody biotech with a discovery platform producing multi-specific therapeutic proteins for cancer and rare diseases, sharing HiFiBiO's engineered-antibody discovery platform origin.
- Zymeworks: Clinical-stage biotech with antibody engineering platforms (Azymetric, ZymeLink) used to develop multispecific antibody therapeutics, comparable as a platform-enabled antibody developer with pharma partnerships.
- Akeso: China-based clinical-stage biotech developing a large bispecific/multispecific antibody pipeline for cancer and autoimmune diseases, comparable to HiFiBiO's Asia-Pacific antibody development operations and IO/I&I therapeutic focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
HiFiBiO Cambridge social profiles
Digital presenceHiFiBiO Cambridge financial estimates
Financial estimateRevenue estimate
Valuation estimate
HiFiBiO Cambridge leadership team
Management profileNumber of profiles
Profiles8 records
HiFiBiO Cambridge subsidiaries and ownership
Company hierarchySubsidiaries3 records
HiFiBiO Cambridge funding detail
Funding detailFunding overview
Funding rounds5 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HiFiBiO Cambridge M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HiFiBiO Cambridge
What does HiFiBiO Cambridge do?
HiFiBiO Therapeutics is a clinical-stage biotech that develops transformative immunotherapies for cancer and autoimmune diseases using its proprietary Drug Intelligence Science (DIS®) platform, which combines single-cell technology with AI/ML analytics. The company advances an internal pipeline of monoclonal antibody candidates (e.g., Emunkitug, Nuvustotug, HFB200603, HFB200604) and monetizes select assets through out-licensing and co-development partnerships with pharmaceutical companies.
Is HiFiBiO Cambridge a public or private company?
HiFiBiO Cambridge is a private company. It is classified as venture growth investor backed and is currently operating.
When was HiFiBiO Cambridge founded?
HiFiBiO Cambridge was founded in 2017. It employs 51 to 100 people.
Where is HiFiBiO Cambridge based?
HiFiBiO Cambridge is headquartered in Cambridge, United States, in the North America region.
How does HiFiBiO Cambridge make money?
Two revenue lines are on record. Partnership and Licensing Revenue is the primary driver. The others are internal Pipeline Development and Commercialization.
Who are HiFiBiO Cambridge's main competitors?
Direct peers on record are Werewolf Therapeutics, Compass Therapeutics, Adagene, Compugen, Atreca, NextCure, Cue Biopharma, Inhibrx Biosciences, Zymeworks and Akeso.
Does HiFiBiO Cambridge have an API?
No public API is recorded for HiFiBiO Cambridge.
What industry is HiFiBiO Cambridge in?
HiFiBiO Cambridge's product category is Clinical-stage biotherapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 325414 and its SIC code is 2836.